Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis

Annals of Surgical Oncology

Volumn 20, Issue 9, 2013, Pages 2858-2865

  Park, Seho ^a   Park, Ji Min ^a   Cho, Jung Hoon ^a   Park, Hyung Seok ^a   Kim, Seung Il ^a   Park, Byeong Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; PHYTATE; TECHNETIUM 99M;

ADJUVANT CHEMOTHERAPY; ADULT; BREAST CANCER; CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84881476996     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2992-8     Document Type: Conference Paper

References (34)

1. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85.
2. Berruti A, Generali D, Kaufmann M, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011;2011:147-51.
3. Untch M, von Minckwitz G. Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res. 2009;11:203.
4. Ho A, Morrow M. The evolution of the locoregional therapy of breast cancer. Oncologist. 2011;16:1367-79.
5. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129:675-89.
6. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2009;7:122-92.
7. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304-11.
8. Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116:2884-9.
9. Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14:2946-52.
10. Gimbergues P, Abrial C, Durando X, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008;15:1316-21.
11. van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124-30.
12. Canavese G, Dozin B, Vecchio C, et al. Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes. Eur J Surg Oncol. 2011;37:688-94.
13. Brown AS, Hunt KK, Shen J, et al. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 2010;116:2878-83.
14. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer. 2010;116:1243-51.
15. Takei H, Yoshida T, Kurosumi M, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation. Int J Clin Oncol. 2012. doi: 10.1007/s10147-012-0418-4.
16. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4-16.
17. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-8.
18. Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22, 2001, Philadelphia, Pennsylvania. Hum Pathol. 2002;33:579-89.
19. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-20.
20. Oh JW, Jung SY, Hur H, et al. The result of evaluation according to radioactivity of sequential sentinel nodes biopsy in breast cancer. J Breast Cancer. 2006;9:235-40.
21. Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park BW. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer. 2011;14:296-300.
22. Edge SB, Byrd DR, Compton CC, Fritiz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
25. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95.
26. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45.
27. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72-8.
28. Chawla A, Hunt KK, Mittendorf EA. Surgical considerations in patients receiving neoadjuvant systemic therapy. Future Oncol. 2012;8:239-50.
29. Dixon JM, Cody HS, 3rd. Role of sentinel node biopsy in patients having neoadjuvant chemotherapy. Eur J Surg Oncol. 2010;36:511-3.
30. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005;92:14-23.
31. Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558-66.
32. Pecha V, Kolarik D, Kozevnikova R, et al. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer. 2011;117:4606-16.
33. Ota D, Nelson H. Targeted surgical procedures in oncology: Z1071 sentinel node protocol. Bull Am Coll Surg. 2009;94:38-9.
34. Kühn T, Bauerfeind I, Fehm T, et al. Sentinel-node biopsy before or after neoadjuvant systemic treatment: the German SENTINA trial. ASCO Mtng Abstr. 2010;28:TPS114.